


AMENDMENTS TO THE CLAIMS

1-20. (Canceled)

21. (Currently Amended) A compound of formula III



wherein R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, straight chained C<sub>1-6</sub> alkyl group optionally substituted with a phenyl group, branched C<sub>1-6</sub> alkyl group optionally substituted with a phenyl group, or R<sub>1</sub> and R<sub>2</sub> together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms ~~heteroatom~~, wherein said heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups;

~~A is a phenyl group optionally substituted with one or more C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, nitro, or halogen, or is a 5-6 membered N-containing heteroaromatic ring containing at least one heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur, wherein the nitrogen heteroatom is optionally having a [[an]] N-oxide structure on the nitrogen heteroatom;~~

n is 0, 1, or 2;

z is 0 or 1;

~~with the proviso that~~

~~if R<sub>1</sub> and R<sub>2</sub> independently represent a hydrogen atom, a straight chained C<sub>1-6</sub> alkyl group optionally substituted with a phenyl group, a branched C<sub>1-6</sub> alkyl group optionally substituted with a phenyl group, or together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom; then A is a heteroaromatic ring containing oxygen or sulfur heteroatom or an N-containing heteroaromatic ring having an N-oxide structure on the nitrogen heteroatom and~~

~~if A is a phenyl group optionally substituted with one or more C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or nitro groups or halogen, or is a 5-6 membered N-containing heteroaromatic ring, then R<sub>1</sub> and R<sub>2</sub> together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo, or benzyl groups;~~  
or a stereoisomer or salt thereof.

22-26. (Canceled)

27. (Previously Presented) The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(1-piperidiny)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

28-29. (Canceled)

30. (Previously Presented) The compound according to claim 27, wherein the compound is (+)-5,6-dihydro-5-[(1-piperidiny)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

31. (Previously Presented) The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(1-oxido-1-piperidiny)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.


32-34. (Canceled)

35. (Previously Presented) A pharmaceutical composition comprising a compound of formula III as defined in claim 21 and a pharmaceutically acceptable carrier.

36-37. (Canceled)

38-42. (Not Entered)

43. (New) A compound of formula III



wherein  $R_1$  and  $R_2$  together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo or benzyl groups;

A is a phenyl group optionally substituted with one or more  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl, nitro, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom selected from nitrogen, oxygen, and sulfur, wherein the nitrogen heteroatom optionally has a N-oxide structure;

n is 0, 1, or 2;

z is 0 or 1;

or a stereoisomer or salt thereof.

44. (New) The compound according to claim 43, wherein the compound is 5,6-dihydro-5-[(4-benzyl-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

45. (New) The compound according to claim 43, wherein the compound is 5,6-dihydro-5-[(2-oxo-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

46. (New) The compound according to claim 43, wherein the compound is 5,6-dihydro-5-[(4-hydroxy-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

47. (New) A pharmaceutical composition comprising a compound of formula III as defined in claim 43 and a pharmaceutically acceptable carrier.